Market Closed -
Nasdaq
04:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
1.22
USD
|
+7.96%
|
|
+7.96%
|
+37.65%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,742
|
3,376
|
1,307
|
1,505
|
87.16
|
112.4
|
-
|
-
|
Enterprise Value (EV)
1 |
3,742
|
3,376
|
1,307
|
1,505
|
87.16
|
112.4
|
112.4
|
112.4
|
P/E ratio
|
-48.2
x
|
-17.6
x
|
-4.49
x
|
-5.1
x
|
-0.3
x
|
-0.73
x
|
-1.21
x
|
-1.59
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.6
x
|
19.1
x
|
5.56
x
|
10.7
x
|
0.59
x
|
0.75
x
|
0.74
x
|
0.63
x
|
EV / Revenue
|
14.6
x
|
19.1
x
|
5.56
x
|
10.7
x
|
0.59
x
|
0.75
x
|
0.74
x
|
0.63
x
|
EV / EBITDA
|
-47.9
x
|
-19.9
x
|
-4.78
x
|
-5.18
x
|
-0.34
x
|
-0.77
x
|
-1.31
x
|
-1.67
x
|
EV / FCF
|
-44,303,163
x
|
43,495,355
x
|
-14,953,559
x
|
-10,056,537
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
87,250
|
91,011
|
92,710
|
93,958
|
98,340
|
99,475
|
-
|
-
|
Reference price
2 |
42.89
|
37.09
|
14.10
|
16.02
|
0.8863
|
1.130
|
1.130
|
1.130
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
256.6
|
176.3
|
235.3
|
140.7
|
147.8
|
150.4
|
152.4
|
179.5
|
EBITDA
1 |
-78.17
|
-169.8
|
-273.7
|
-290.4
|
-259.3
|
-146.8
|
-85.78
|
-67.2
|
EBIT
1 |
-89.31
|
-191.9
|
-288.5
|
-301
|
-269.2
|
-151.5
|
-89.42
|
-68.47
|
Operating Margin
|
-34.81%
|
-108.83%
|
-122.62%
|
-213.9%
|
-182.2%
|
-100.75%
|
-58.66%
|
-38.15%
|
Earnings before Tax (EBT)
1 |
-76.64
|
-188.9
|
-290.7
|
-294.9
|
-286.9
|
-153.6
|
-93.9
|
-70.75
|
Net income
1 |
-76.97
|
-189.3
|
-290
|
-293.7
|
-284.2
|
-153.6
|
-93.9
|
-70.75
|
Net margin
|
-30%
|
-107.36%
|
-123.25%
|
-208.66%
|
-192.37%
|
-102.11%
|
-61.6%
|
-39.42%
|
EPS
2 |
-0.8900
|
-2.110
|
-3.140
|
-3.140
|
-2.920
|
-1.550
|
-0.9350
|
-0.7100
|
Free Cash Flow
|
-84.47
|
77.61
|
-87.42
|
-149.7
|
-
|
-
|
-
|
-
|
FCF margin
|
-32.92%
|
44.02%
|
-37.15%
|
-106.35%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
16.54
|
60.83
|
29.81
|
15.74
|
34.37
|
36.16
|
44.32
|
40.13
|
27.14
|
55.9
|
35.06
|
33.64
|
31.49
|
33.06
|
EBITDA
|
-132.7
|
-60.41
|
-75.57
|
-90.98
|
-
|
-73.13
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-135.2
|
-62.99
|
-78.22
|
-93.66
|
-66.15
|
-76.09
|
-88.05
|
-50.88
|
-54.2
|
-31.06
|
-28.75
|
-37.4
|
-42.88
|
-28.53
|
Operating Margin
|
-817.51%
|
-103.56%
|
-262.44%
|
-595.21%
|
-192.48%
|
-210.42%
|
-198.67%
|
-126.77%
|
-199.71%
|
-55.57%
|
-81.99%
|
-111.16%
|
-136.16%
|
-86.29%
|
Earnings before Tax (EBT)
|
-134.3
|
-63.41
|
-73.17
|
-91.94
|
-66.35
|
-77.43
|
-88.46
|
-64.21
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-134.1
|
-63.2
|
-72.62
|
-91.65
|
-66.18
|
-76.7
|
-87.68
|
-63.62
|
-
|
-
|
-24.48
|
-41.76
|
-47.13
|
-
|
Net margin
|
-810.49%
|
-103.91%
|
-243.66%
|
-582.46%
|
-192.55%
|
-212.12%
|
-197.84%
|
-158.51%
|
-
|
-
|
-69.84%
|
-124.11%
|
-149.66%
|
-
|
EPS
2 |
-1.450
|
-0.6800
|
-0.7800
|
-0.9800
|
-0.7000
|
-0.8100
|
-0.9000
|
-0.6500
|
-0.5700
|
-0.3300
|
-0.3600
|
-0.4200
|
-0.4650
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/27/23
|
5/8/23
|
8/7/23
|
11/6/23
|
2/26/24
|
5/6/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-84.5
|
77.6
|
-87.4
|
-150
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-40.4%
|
-91.9%
|
-255%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
0.9100
|
-0.8900
|
-1.560
|
3.240
|
-0.4000
|
0.0200
|
-
|
Capex
|
5.76
|
3.99
|
5.19
|
3.74
|
-
|
-
|
-
|
-
|
Capex / Sales
|
2.25%
|
2.27%
|
2.2%
|
2.66%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
1.13
USD Average target price
1.75
USD Spread / Average Target +54.87% Consensus |
1st Jan change
|
Capi.
|
---|
| +37.65% | 112M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|